The present disclosure provides methods of using zilucoplan as a therapy for AChR positive gMG patients non-refractory to conventional immunosuppressive therapy and/or intravenous (IV) immunoglobulin and plasma exchange (PLEX) therapy.

Described herein are compositions and methods for bioluminescent analyte detection. In some embodiments, a recombinant bioluminescent polypeptide sensor is disclosed comprising a luminescent signaling domain, an analyte binding domain, and one or more peptide linkers, wherein the luminescent signaling domain is oriented in relation to the analyte binding domain such that binding of an analyte to the analyte binding domain induces a conformational change in the luminescent signaling domain to generate a luminescent signal.